CA
MRNA icon

Cetera Advisors’s Moderna MRNA Stock Holding History

Cetera Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.35M Buy
12,669
+8,419
+198% +$849K 0.01% 1010
2023
Q4 		$423K Sell
4,250
-1,184
-22% -$99.6K 0.01% 1222
2023
Q3 		$561K Buy
5,434
+173
+3% +$19.3K 0.01% 995
2023
Q2 		$639K Sell
5,261
-13
-0.2% -$1.73K 0.01% 926
2023
Q1 		$810K Sell
5,274
-351
-6% -$57.9K 0.01% 781
2022
Q4 		$1.01M Buy
5,625
+484
+9% +$79.1K 0.02% 667
2022
Q3 		$608K Sell
5,141
-802
-13% -$122K 0.02% 697
2022
Q2 		$849K Buy
5,943
+296
+5% +$42.3K 0.02% 628
2022
Q1 		$973K Sell
5,647
-7,746
-58% -$1.3M 0.02% 621
2021
Q4 		$3.4M Sell
13,393
-1,430
-10% -$418K 0.07% 283
2021
Q3 		$5.71M Buy
14,823
+867
+6% +$320K 0.11% 190
2021
Q2 		$3.28M Sell
13,956
-516
-4% -$92.2K 0.08% 256
2021
Q1 		$1.9M Buy
14,472
+489
+3% +$70.9K 0.05% 329
2020
Q4 		$1.46M Buy
13,983
+1,223
+10% +$124K 0.05% 337
2020
Q3 		$903K Buy
12,760
+418
+3% +$29.1K 0.03% 392
2020
Q2 		$792K Buy
+12,342
New +$676K 0.03% 420

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's MRNA Position: Q1 2024 in Review

Cetera Advisors increased its Moderna (MRNA) stake by 198% in Q1 2024, buying an estimated $849K and bringing the position to 12,669 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #1010.

Cetera Advisors first reported a position in MRNA in Q2 2020 and has held it in 16 quarters since. The position peaked at $5.71M in Q3 2021. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Cetera Advisors held 12,669 shares of Moderna worth $1.35M as of Q1 2024.
  • Cetera Advisors bought 8,419 Moderna shares in Q1 2024, an estimated $849K.
  • Moderna made up 0.01% of Cetera Advisors's portfolio in Q1 2024, its #1010 holding.
  • Cetera Advisors first reported a position in Moderna in Q2 2020 and has held it in 16 quarters since.
  • Cetera Advisors's Moderna position peaked at $5.71M in Q3 2021.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.